EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
GlobeNewswire - Mon May 04, 8:03AM CDT
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"
EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:40PM CDT
Eyegate Pharmaceuticals, Inc. (OTCBB:EYEG) ("EyeGate" or the "Company"
Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer
GlobeNewswire - Mon Mar 02, 7:35AM CST
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate"
InsiderInsights.com Daily Round Up 2/23/15: MDLZ, GPRO, MDGN, CRR
InsiderInsights - at Seeking Alpha - Tue Feb 24, 6:07AM CST
GPRO: 50.09 (-0.53), LDRH: 39.27 (+0.48), MDLZ: 40.45 (+0.40), HCOM: 25.39 (-0.11), CRR: 43.75 (-0.23), MDGN: 7.38 (-0.27), DEI: 29.50 (+0.27), WETF: 18.51 (-0.45), BBY: 34.59 (-0.23), AON: 99.55 (-0.43), GOOG: 533.85 (-4.55), LEA: 114.47 (+0.05), AJX: 13.18 (+0.10), PLAY: 33.04 (-0.03), CTSH: 63.57 (-0.25), BLPH: 8.66 (+0.14), OMI: 33.68 (+0.03)
Eyegate Pharma closes IPO
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 11:42AM CST
Eyegate Pharma prices IPO
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:13AM CST
IPO Market Set For Another Surge In The Healthcare Sector
Renaissance Capital IPO Research - at Seeking Alpha - Mon Feb 02, 6:15PM CST
Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the two dividend-producing IPOs seek to price late in the week. The remaining eight...
AVGR: 11.31 (+0.07), IDGX: (), SLWD: (), ITEK: 5.80 (-0.06), REDX: (), INOV: 25.70 (+1.75), PUMP: (), CBYL: 7.70 (+0.46), NVET: 7.32 (-0.32), AAAP: ()
EyeGate Pharma back resets for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:29PM CST
Week Ahead: IPO Market Gains Momentum With 12 Deals Including Shake Shack And Health Care
Renaissance Capital IPO Research - Seeking Alpha - Tue Jan 27, 7:03AM CST
Twelve IPOs are set to raise $1 billion in the upcoming week, which would make it the busiest five-day stretch for IPOs since the week of July 28. Shake Shack's IPO offers investors a chance to own a fast-growing fast casual concept based in New...
AVGR: 11.31 (+0.07), SHAK: 69.39 (+3.89), ASND: 17.28 (-0.10), HIFR: 30.56 (+0.02), REDX: (), ONCE: 56.86 (+0.06), ENTL: 24.82 (+0.03), ZSAN: 10.41 (+0.63), FLKS: 17.17 (+0.19), LENS: 8.79 (-0.21), TCON: 12.27 (+1.41)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 240.22 (+2.88), OHRP: 2.73 (-0.02), REGN: 489.01 (-2.42), OMER: 20.88 (-0.01), NVS: 103.75 (-0.15)
Cataract Therapeutic Pipeline Market Review by Companies and Drugs H2 2014 Report at RnRMarketResearch.com
PRWeb - Fri Nov 21, 7:31AM CST
The report "Cataract - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/cataract-pip...eport.html .
Solar Power, Biotechs Among 11 IPOs Planned This Week
at Investor's Business Daily - Mon Sep 29, 6:24PM CDT
The IPO market is maintaining a brisk pace with 11 scheduled this week, including a solar power company, three tech firms and three biotech companies. Vivint Solar (VSLR), a competitor to the Elon Musk-backed SolarCity (SCTY), plans to raise $350...
ATTO: 13.07 (-0.08), VWR: 27.40 (+0.08), JMEI: 25.35 (-1.33), ZEN: 22.29 (-0.30), VSLR: 13.92 (-0.23), JPEP: 13.34 (-0.01), W: 29.05 (+0.54), FMSA: 8.83 (+0.05), SCTY: 62.51 (-0.21), DERM: 14.97 (-0.07), AAC: 37.01 (+0.63), CALA: 11.87 (-0.27), AAVL: 35.10 (-0.85), YDLE: 14.38 (-0.25), JD: 33.40 (+0.02), BABA: 88.46 (+0.06)